Key Highlights

  • Genelux (NASDAQ:GNLX) reported a third-quarter net loss of USD 10.3 million, or USD 0.23 per share, compared with USD 8.0 million, or USD 0.21 per share, a year earlier.
  • Research and development expense rose USD 2.2 million to USD 6.9 million, driven by clinical costs in the Phase 3 On Prime/GOG-3076 registration trial.
  • Cash, restricted cash and marketable securities were USD 10.4 million at September 30, 2026, and USD 5.1 million of net proceeds arrived in October and November.
  • Management expects the pro forma USD 15.5 million to fund operations into the first quarter of 2027, and the filing carries a Going Concern warning.

Phase 3 Spending Pushes the Quarterly Loss Higher

Genelux (NASDAQ:GNLX) filed its Quarterly Report on November 16, 2026. Genelux is a late clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies, with lead candidate Olvi-Vec, a modified vaccinia virus intended to kill tumor cells and trigger an immune response. The company has no approved products and recorded no Revenue in either period. The third-quarter net loss was USD 10.3 million against USD 8.0 million a year earlier, or USD 0.23 per share against USD 0.21. Operating expenses were USD 10.4 million, up from USD 8.2 million, and other income fell to USD 0.1 million from USD 0.2 million on lower interest income. The company has said it expects expenses to keep rising as it advances its candidates through clinical development and manufacturing, so quarterly losses may stay elevated.

Clinical Costs Drive a USD 2.2 Million Jump in R&D

Research and development expense reached USD 6.9 million, up from USD 4.7 million. Clinical and regulatory costs nearly doubled to USD 3.9 million from USD 2.0 million as enrollment costs grew in the Phase 3 On Prime/GOG-3076 registration trial. Employee compensation in research rose to USD 1.2 million from USD 0.9 million, while Manufacturing materials and quality services costs declined. General and administrative expense was nearly flat at USD 3.5 million, with higher Stock Compensation of USD 1.8 million offset by lower employee costs. Over nine months, the net loss was USD 28.7 million, or USD 0.64 per share, compared with USD 22.9 million, or USD 0.62.

Going Concern Language and the Funding Path

The filing states that recurring losses raise substantial doubt about the ability to continue as a going concern. Cash used in operations was USD 18.4 million over nine months, and the accumulated Deficit stood at USD 312.2 million. Financing inflows of USD 19.3 million came largely from a January 2026 offering of 6,666,667 shares at USD 3.00, which raised USD 18.5 million net, plus small at-the-market sales. In October and November, 2,552,458 shares were sold through the at-the-market program for USD 5.1 million net. Stockholders Equity was USD 9.2 million, and 45,488,978 shares were outstanding at September 30, 2026. A licensing partner in China and Taiwan has paid USD 11.0 million to date.

Where Things Stand

The loss widened because the Phase 3 trial is getting more expensive, and funding is the open question. Genelux (NASDAQ:GNLX) lost USD 10.3 million in the quarter, and clinical costs account for most of the increase in spending. Pro forma cash of USD 15.5 million is expected to last into the first quarter of 2027, which is close given a quarterly burn near USD 10 million, and the filing notes that estimate could prove wrong. Further equity sales or Partnership funding would be the next events to watch, along with trial progress.